Patents by Inventor Paul C. Levesque

Paul C. Levesque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies which bind variants of the TRP channel family member, LTRPC3
    Patent number: 7705133
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: April 27, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, Shujian Wu, Michael A. Blanar, Paul C. Levesque, Lucy Sun
  • KCNQ2 potassium channels
    Patent number: 7482431
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: January 27, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Blanar, Paul C. Levesque, Wayne A. Little, Michael G. Neubauer, Wen-Pin Yang
  • Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3
    Publication number: 20080318257
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: July 22, 2008
    Publication date: December 25, 2008
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Michael A. Blanar, David K. Bol, Paul C. Levesque, Lucy Sun
  • Variants of the TRP channel family member, LTRPC3G
    Patent number: 7459532
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: December 2, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, Shujian Wu, Michael A. Blanar, Paul C. Levesque, Lucy Sun
  • Polynucleotides encoding variants of the TRP channel family member, LTRPC3
    Patent number: 7344882
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: March 18, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, Shujian Wu, Michael A. Blanar, Paul C. Levesque, Lucy Sun
  • KCNQ potassium channels and methods of modulating same
    Patent number: 7262289
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: August 28, 2007
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Michael A. Blanar, Wen-Pin Yang, Paul C. Levesque, Michael G. Neubauer, Wayne A. Little
  • DNA encoding rodent KCNQ2 potassium channel
    Patent number: 7041496
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: May 9, 2006
    Assignee: Bristol-Myers Squibb
    Inventors: Michael A. Blanar, Steven Dworetzky, Wen-Pin Yang, Paul C. Levesque, Valentin K. Gribkoff, Michael G. Neubauer, Wayne A. Little
  • Polynucleotides encoding novel variants of the TRP channel family member, LTRPC3
    Publication number: 20040229315
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: May 10, 2004
    Publication date: November 18, 2004
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Michael A. Blanar, David K. Bol, Paul C. Levesque, Lucy Sun
  • Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof
    Publication number: 20030224450
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: March 28, 2003
    Publication date: December 4, 2003
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Liana M. Lee, Michael A. Blanar, David Bol, Paul C. Levesque, Lucy Sun
  • Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof
    Publication number: 20030162189
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: August 1, 2002
    Publication date: August 28, 2003
    Inventors: Ning Lee, Jian Chen, John Feder, Shujian Wu, Liana Lee, Michael A. Blanar, David Bol, Paul C. Levesque, Lucy Sun
  • KCNQ potassium channels and methods of modulating same
    Publication number: 20030044912
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Application
    Filed: April 24, 2002
    Publication date: March 6, 2003
    Inventors: Michael A. Blanar, Wen-Pin Yang, Paul C. Levesque, Michael G. Neubauer, Wayne A. Little
  • KCNQ potassium channels and methods of modulating same
    Publication number: 20020168724
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Application
    Filed: April 24, 2002
    Publication date: November 14, 2002
    Inventors: Michael A. Blanar, Steven Dworetzky, Wen-Pin Yang, Paul C. Levesque, Valentin K. Gribkoff, Michael G. Neubauer, Wayne A. Little
  • KCNQ potassium channels and methods of modulating same
    Patent number: 6403360
    Abstract: The present invention relates to KCNQ proteins defining potassium channels. In particular, the invention concerns the human KCNQ2, human KCNQ3, murine KCNQ2, and rat KCNQ2 proteins reported herein. KCNQ2 and KCNQ3 proteins are nervous system-selective and may be involved in neurotransmission and neuroprotection. The KCNQ2 and KCNQ3 of the present invention can be used to assay for modulators of the proteins, which would be useful in treatment of such disorders as ataxia, myokymia, seizures, Alzheimer's disease, Parkinson's disease, age-associated memory loss, learning deficiencies, motor neuron diseases, epilepsy, stroke, and the like.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: June 11, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Blanar, Paul C. Levesque, Wayne A. Little, Michael G. Neubauer, Wen-Pin Yang